항생제
Entecavir

Entecavir

Spectrum Of Activity

General Information

Active type B viral hepatitis, chronic.

Black Box Warning: Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely for at least several months after discontinuation. Initiation of anti-hepatitis B therapy may be warranted. Entecavir is not recommended in patients co-infected with HIV and HBV who are not also receiving highly active antiretroviral therapy (HAART) because of the potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors.

Monitor AST/ALT, HBV envelope antigen, HBV surface antigen, and HBV DNA levels every 3 months for first year of therapy and annually thereafter during treatment.

HIV antibody testing should be offered to all patients.

Monitor hepatic function for several months after discontinuing therapy.

Monitor renal function at baseline and during therapy, especially in the elderly and in liver transplant patients on immunosuppressants.

Monitor urinalysis and serum phosphate prior to therapy and at least annually during therapy.

Common

  • Nausea
  • Fatigue
  • Headache
  • Dizziness

Severe

  • Lactic acidosis
  • Hepatomegaly (with steatosis)
  • Recurrent hepatitis

No significant interactions

Antimicrobial class: Antiviral agent, Guanosine nucleoside analog

Pregnancy category: C

Average serum half life: 128-149 hours

Precautions:

  • Dose adjustment recommended in patients with renal impairment (CrCl <50 mL/min).
  • Suspend treatment if signs or symptoms of lactic acidosis or hepatotoxicity occur.
  • Use caution in liver transplant recipients, with past or current use of an immunosuppressant which may affect renal function (e.g. cyclosporine, tacrolimus); renal function monitoring recommended.
  • Entecavir is not recommended in patients co-infected with HIV/HBV who are not receiving concurrent HIV treatment